Covid Research

Home>Tag: Covid Research
Apr 26 2021

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Treating and Curing Covid-19 Infection Utilizing a Laser

By |2021-04-25T23:01:11-04:00April 26th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, April 26, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Treating and Curing Covid-19 Infection Utilizing a Laser.”  The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William ...

Dec 7 2020

Halberd Corp. Research Yields Promising SARS-CoV-2 Antibody in Laboratory Testing

By |2020-12-06T16:39:08-05:00December 7th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 7, 2020 – Halberd Corporation (OTC PINK: "HALB") announced the promising results of laboratory testing on their new patent pending SARS-COV-2 monoclonal antibody generated through their university research.  The antibody testing to date has shown extremely potent action against the SARS-CoV-2 spike protein.  Scientific details of the testing to date will ...

Dec 2 2020

Halberd Corporation’s Covid-19 Technology Recognized by Momentum Observer

By |2020-12-01T19:46:42-05:00December 2nd, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 2, 2020 – Halberd Corp. (OTC PINK: "HALB") was recently included in a Momentum Observer article on Covid-19 along with big pharma companies Pfizer (PFE: NYSE), Moderna (MRNA: NASDAQ), BioNTech (BNTX: NASDAQ) and AstraZeneca (AZN: NASDAQ).  The article featured Halberd's nasal spray currently under development that could be an effective alternative ...

Nov 25 2020

Halberd Corp. CEO Interviewed on Money TV;
Discusses 2020 Accomplishments and Plans

By |2020-11-24T20:59:01-05:00November 25th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 25, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed this week by host, Donald Baillargeon, on Money TV.  Mr. Hartman recapped the company’s accomplishments, describing its most promising technologies and described the unique applications perceived, including a sneak peek at the future. Mr. Hartman ...

Nov 12 2020

Halberd Corporation Reveals Patent-Pending Fluorescent Antibody’s Wide Role in Covid-19 Detection & Treatment

By |2020-11-11T20:25:36-05:00November 12th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 12, 2020 – Halberd Corporation (OTC PINK: "HALB") today disclosed information on their patent-pending fluorescent anti-Spike protein monoclonal antibodies against Covid-19 developed in conjunction with Dr. Qiang (Shawn) Chen of Arizona State University.  The salient feature of Halberd’s new class of antibody is that it fluoresces in the presence of Covid-19 ...

Sep 28 2020

Arizona State University/Halberd Pursue Nasal Spray As Covid-19 Preventative/Treatment Based On Children’s Natural Immunity

By |2020-09-27T19:42:54-04:00September 28th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 28, 2020 – Children are far less susceptible than adults to the Coronavirus (1, 2).  Halberd Corporation’s (OTC PINK: "HALB") scientists have determined the reason may be that adults have far more Angiotensin-Converting Enzyme 2 (ACE2) receptors in nasal membrane epithelial cells.  ACE2 (3) is a membrane protein expressed in many ...

Sep 24 2020

Arizona State University/Halberd Corp. Covid-19 R&D Program Rapid Diagnostic Test / Treatment

By |2020-09-23T20:35:03-04:00September 24th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 24, 2020 – Halberd Corporation (OTC PINK: "HALB") clarifies next steps in their unique research with Arizona State University.  Halberd directed their research program to focus on that element of Covid-19 which makes the disease most contagious -- the spike antigen. ASU investigators have projected the production of the coronavirus spike ...

Sep 21 2020

Arizona State University/Halberd Corp. Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen Re-Creation!

By |2020-09-20T20:34:28-04:00September 21st, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 21, 2020 – Halberd Corporation (OTC PINK: "HALB") released a progress update on the research being conducted in conjunction with Arizona State University researchers.  Dr. Qiang Chen, ASU’s lead researcher, reports the successful re-creation of the coronavirus spike protein disease antigen in laboratory research. With this breakthrough, Dr. Chen’s team will ...

Sep 17 2020

Arizona State University/Halberd Corp. Outline Partnership 2nd Stage Goals of $1.4 M Covid-19 Program

By |2020-09-17T08:26:31-04:00September 17th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 17, 2020 – Halberd Corporation (OTC PINK: "HALB") today outlined the specifics of the second stage goals of the $1.4 Million seven-phase research project with Arizona State University. The second stage of the research involves an investigation of a method using dialysis, or a variant of dialysis, to remove the fluorescent ...

Sep 14 2020

Halberd Corporation Outlines Multi-Phase $1.4 M Covid-19 Program in Partnership With ASU

By |2020-09-13T20:36:48-04:00September 14th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 14, 2020 – Halberd Corporation (OTC PINK: "HALB") today released the specifics of the initial phase of the $1.4 Million seven-phase research project with Arizona State University. The University project for a rapid test to identify Covid-19 infection, from a sample such as saliva, mucus, blood and CSF will be based ...

Go to Top